Evolent Health Business Summary

Evolent Health, Inc. (EVH) operates as a specialized value-based care enablement platform, primarily generating revenue through a mix of recurring subscription-based technology fees and risk-based transaction fees. The company’s business is organized into three core product lines: the Performance Suite, which utilizes a capitated, at-risk model where Evolent manages the total cost of specialty care; the Specialty Technology and Services Suite, offering fee-for-service clinical and administrative solutions; and Administrative Services, providing comprehensive health plan infrastructure. Following the 2025 divestiture of its primary care business, Evolent has pivoted aggressively toward high-cost specialty management in oncology, cardiology, and musculoskeletal care. It competes directly with integrated giants like Optum (UnitedHealth Group) and specialized peers such as Astrana Health, Lumeris, and Aledade, positioning itself as a tech-first alternative that bridges the gap between clinical outcomes and financial risk for payers and providers. Evolent was co-founded in 2011 by Frank Williams, who currently serves as Executive Chairman, and Seth Blackley, the company’s Chief Executive Officer. The leadership team includes President Dan McCarthy, Chief Operating Officer Katie DiPerna, and Chief Technology Officer Rob Cruz, who brings over two decades of healthcare engineering expertise from firms like CPSI. In a significant 2026 leadership transition, Mario Ramos assumed the role of Chief Financial Officer, succeeding John Johnson, who moved into the Chief Strategy Officer position. The company’s strategic direction is heavily influenced by a high-pedigree board featuring Richard Jelinek (Chair), Cityblock CEO Toyin Ajayi, and former CVS Health CFO Shawn Guertin. Notable institutional backing remains strong from early investor TPG Growth, alongside major stakeholders Vanguard and BlackRock, while activist investor Engaged Capital maintains a significant stake to drive operational efficiency and margin expansion.